Clinical Trials Browser

Terminated × Lymphoma × Nivolumab × Clear all

Lymphoma, Multiple Myeloma

NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT04730349 2023-03-24

PIVOT IO 020

Phase 1/2 Terminated

15 enrolled 14 charts

CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

NCT03588936 2021-10-11

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Phase 1 Terminated

2 enrolled

LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes

Clinical Trials

CPIT001

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

PIVOT IO 020

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant